Hsp90 and Co-Chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy

Hsp90 and Co-Chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy Publisher Pubmed

Jafari A^{1, 2} ; Rezaeitavirani M² ; Farhadihosseinabadi B³ ; Taranejoo S⁴ ; Zali H⁵

Show Affiliations

1. Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Proteomics Research Center, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Neuroscience Research Center (NRC), Iran University of Medical Sciences, Tehran, Iran
4. Wellman Centre for Photomedicine, Harvard-MIT Division of Health Sciences and Technology (HST), Boston, MA, United States
5. Department of Tissue engineering and applied cell, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Cancer Investigation Published:2020

Abstract

Heat shock protein 90 (HSP90), a highly and unique chaperone, presents as a double-edged sword. It plays an essential role in many physiological and pathological processes, including tumor development. The current review highlights a recent understanding of the roles of HSP90 in molecular mechanisms underlying cancer survival and progression. HSP90 and its client proteins through the regulation of oncoproteins including signaling proteins, receptors, and transcriptional factors involved in tumorigenesis. It also has potential clinical application as diagnostic and prognostic biomarkers for assessing cancer progression. In this way, using HSP90 to develop new anticancer therapeutic agents including HSP90 inhibitors, anti-HSP90 antibody, and HSP90-based vaccines has been promising. © 2020, © 2020 Taylor & Francis Group, LLC.

Related Docs

1. Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis, Current Molecular Pharmacology (2020)

2. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)

3. Autophagy Modulation in Breast Cancer Utilizing Nanomaterials and Nanoparticles, Frontiers in Oncology (2023)

4. The Role of the Tumor Microenvironment in Colorectal Cancer and the Potential Therapeutic Approaches, Journal of Clinical Laboratory Analysis (2022)

5. The Molecular Signature of Breast Cancer Metastasis to Bone, Anti-Cancer Drugs (2016)

Style	Citing Format
MLA	Jafari A, et al.. "Hsp90 and Co-Chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy." Cancer Investigation, vol. 38, no. 5, 2020, pp. 310-328.
APA	Jafari A, Rezaeitavirani M, Farhadihosseinabadi B, Taranejoo S, Zali H (2020). Hsp90 and Co-Chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy. Cancer Investigation, 38(5), 310-328.
Chicago	Jafari A, Rezaeitavirani M, Farhadihosseinabadi B, Taranejoo S, Zali H. "Hsp90 and Co-Chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy." Cancer Investigation 38, no. 5 (2020): 310-328.
Harvard	Jafari A et al. (2020) 'Hsp90 and Co-Chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy', Cancer Investigation, 38(5), pp. 310-328.
Vancouver	Jafari A, Rezaeitavirani M, Farhadihosseinabadi B, Taranejoo S, Zali H. Hsp90 and Co-Chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy. Cancer Investigation. 2020;38(5):310-328.
BibTex	@article{ author = {Jafari A and Rezaeitavirani M and Farhadihosseinabadi B and Taranejoo S and Zali H}, title = {Hsp90 and Co-Chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy}, journal = {Cancer Investigation}, volume = {38}, number = {5}, pages = {310-328}, year = {2020} }
RIS	TY - JOUR AU - Jafari A AU - Rezaeitavirani M AU - Farhadihosseinabadi B AU - Taranejoo S AU - Zali H TI - Hsp90 and Co-Chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy JO - Cancer Investigation VL - 38 IS - 5 SP - 310 EP - 328 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract